Jiangchuan Macrolide Facility Update

Bio-Medicine.Org

CHENGDU, China, July 16 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical (NYSE Amex: TPI [1]), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine and branded generics provides progress update on its Jiangchuan macrolide facility.

The construction of the facility is on schedule, targeting August for completion and equipment installation, immediately followed by GMP certification and trial production. The state-of-the-art macrolide facility, occupying 100mu (~16.5 acres) of land at Sichuan Xinjin Industrial Park near Chengdu, is designed for a total annual capacity of 240 tons of macrolide Active Pharmaceutical Ingredients (API) to serve the growing macrolide antibiotics market.

Jiangchuan macrolide initiative, established in 2009, is designed for the research and development, manufacturing and sales & marketing of API and chemical intermediates of macrolide antibiotics for Azithromycin, Clarithromycin, and Roxithromycin.

Dr. Jiang Guoqing, CEO of Tianyin Pharmaceutical pointed out, "Jiangchuan macrolide initiative expands our scope of business into the large arena of antibiotics. Jiangchuan is not only of great strategic significance and sustainable economic benefits, but also projected to become a leading manufacturer of macrolide antibiotics in China. It captures the growth momentum created by the ongoing healthcare reform. The steady increase of the macrolide raw material prices reaffirmed our market forecast. Additionally, the API business has an efficient profit chain that consists of three key elements: 1) raw material pr
'/>"/>

SOURCE [2]

Source URL (retrieved on *12/11/2013 - 3:02pm*):
http://www.mdtmag.com/news/2010/07/jiangchuan-macrolide-facility-update?qt-recent_content=0

Links:
[1] http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=TPI
[2] http://www.bio-medicine.org/medicine-technology-1/Jiangchuan-Macrolide-Facility-Update-9793-1/